1. Examining CV Effects of Basal Insulin Therapy

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Type 2 Diabetes (T2D) Major Medical and Societal Challenge

4. Glycemic Control ~100 Million People in the United States

5. Basal Insulin Development

6. Basal Insulin Titration in the Treat-to-Target Trial Glargine vs NPH

7. Novel Basal Insulin Glargine U-300

8. More Sustained Reductions in HbA1c With Glargine U-300

9. Participants on Glargine U-300 Had Less Nocturnal Hypoglycemia and Any Time of Day Hypoglycemia

10. Greater Daily Basal Insulin Dose With Glargine U-300 and Less Weight Gain

11. Novel Basal Insulin Degludec

12. Insulin Glargine vs Insulin Degludec Variability

13. Outcome Reduction With an Initial Glargine Intervention ORIGIN Trial

14. Participants in ORIGIN Key Inclusion Criteria

15. Interventions (Added to Lifestyle)

16. Median Glargine Dose & IQR (U/kg)

17. Median HbA1c Levels

18. Hypoglycemia and Weight (6 to 7 years)

19. 1st Co-Primary Endpoint MI, Stroke, or CV Death

20. 2nd Co-Primary Endpoint: MI, Stroke, or CV Death, Revascularization, Heart Failure

21. DEVOTE CVOT with Insulin Degludec Trial Design

22. Time to First 3-Point MACE

23. Basal Insulin Dose (U/kg)

24. Glycemic Control

25. Rates of Severe Hypoglycemia

26. Rates of Nocturnal Severe Hypoglycemia

27. DEVOTE Confirmed the Results From BEGIN and SWITCH With Regards to Hypoglycemia in Patients With T2D

28. Fear of Hypoglycemia Conflicts with Treatment Success for Both Patients and Clinicians

29. Systematic Review: Association of Hypoglycemia With Outcomes

30. Interpreting the Data and Clinical Implications Can We Compare ORIGIN vs DEVOTE?

31. DELIVER 2: Hypoglycemia-Related Data

32. Concluding Remarks

33. Concluding Remarks (cont)

34. Abbreviations

35. Abbreviations (cont)